Lly is to eliminate the adjustment of these EI apatinib because Although a third of the patients experienced myelosuppression, most of these hours Dermatological events were grade 1 or 2 and manageable. Stage 4 M March neutropenia, thrombocytopenia MPC-3100 HSP90 Inhibitors and on Chemistry were only 8.7%, 2.2% and 4.3% of the patients identified, and these AEs may have been related apatinib. VEGF receptors are present on bone marrow stem cells that would be the appearance of bone marrow Ren explained. W During a L Ngeren treatment reduces 38% of patients on the dose due to toxicity Made by various Conna continue Be a clinical benefit, as long as 5.4 months, suggesting a lower dose / bearable K possible further can controlled Legally possible to achieve more the diseases that the 8 predefined weeks.
Significant antitumor activity of t has been observed in patients with measurable AZD0530 Bcr-Abl inhibitor L Emissions. The majority of evaluable patients had either a reduction or stabilization of the tumor by RECIST, which is better than other ITC. Sorafenib has been reported for an SD of 26% in phase I trials. In a pooled analysis of 137 patients in four Phase I studies with sorafenib, only two patients evaluable PR and 38 SD. Most patients had evidence of disease progression by radiological imaging. Strong inhibitory effect on VEGFR-2 plays m for may have an r The key to the most important anti-cancer activity apatinib t compared to other VEGFR ITC took note, however, due to patient selection differences could not be ignored, which is also a comparative prospective study may be necessary.
Apatinib has shown promising results in GIST, as a patient who has not attained PR GIST imatinib, and not so far advanced. RA duration was 24 months. Sunitinib as first-line treatment of renal cell carcinoma admitted with a response rate of 31% and ridiculed Progression-free survival ngerten of 11 months for free. However, Saltz et al recently reported a decrease in the activity T of colorectal carcinoma with sunitinib as monotherapy was noted. Among the 84 patients with colorectal carcinoma, only achieved a PR and 13 stable disease. Sunitinib showed no clinically significant response to monotherapy for patients refractory to target colorectal cancer R compared with standard chemotherapy. In addition, sunitinib has not effectively active against adenocarcinoma of the stomach.
In a report from ASCO GI in 2009 Sunitinib Figure 2 tumor shrinkage after 4 months of treatment with apatinib was compared to baseline best CONFIRMS. Li et al. BMC Cancer 2010, 10:529 2407/10/529 Page 7 of 8 was evaluated for chemotherapy metastatic gastric cancer. Only 5 of 52 patients showed a contr The tumor. Compared with sorafenib and sunitinib shows apatinib good anti-cancer activity for stomach cancer and colon cancer. Rate it controlled The disease of 81% in evaluable patients with gastric cancer and colon cancer 22, including 4 PR was achieved noted. Conclusions The results of this study showed that s apatinib R and was well tolerated and showed significant anti-tumor activity of t at a dose of 750 mg once a day. Promising antitumor activity of t has apatinib in patients with a wide range of advanced solid tumors are detected in this study and apatinib is investigated in ongoing Phase II / III trials. Author Details 1Department of Medical Oncology, Fudan University, Shanghai Cancer